After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
This is the first update to the original CTS communication distributed on July 6th. As previously co...
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....
On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the changes to F...
We sincerely hope to see you at this year’s AABB Annual Meeting in San Antonio, TX on October ...
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...